← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs
atorvastatin, amlodipine and ramipril
C10BX18
Forms & Strengths
- Tablets: 10mg/5mg/2.5mg, 10mg/5mg/5mg, 10mg/10mg/5mg, 20mg/5mg/5mg, 20mg/10mg/5mg, 20mg/10mg/10mg
- Fixed-dose combination
- Film-coated tablets
Adult Dosing
- Dose individually adjusted according to target blood pressure and lipid levels
- Maximum dose: atorvastatin 80mg, amlodipine 10mg, ramipril 10mg
- Initial dose: atorvastatin 10-20mg, amlodipine 5mg, ramipril 2.5-5mg
Pediatric Dosing
- Not recommended for pediatric patients under 18 years
- Limited data available for pediatric use
Indications
- Treatment of hypertension and hyperlipidemia
- Reduction of risk of cardiovascular events
- Treatment of patients with stable coronary artery disease
Mechanism of Action
- Atorvastatin: HMG-CoA reductase inhibitor, reduces cholesterol synthesis
- Amlodipine: Calcium channel blocker, causes vasodilation
- Ramipril: ACE inhibitor, reduces angiotensin II levels
Contraindications
- Hypersensitivity to any component
- Pregnancy and lactation
- Bilateral renal artery stenosis
- Unstable angina or acute myocardial infarction
- Severe hepatic impairment
Adverse Reactions
- Headache, dizziness, fatigue
- Gastrointestinal disorders (nausea, diarrhea)
- Muscle pain, back pain
- Renal dysfunction, hyperkalemia
- Cough, hypotension
Drug Interactions
- Concomitant use with ciclosporin, gemfibrozil, or other statins increases risk of myopathy
- Concomitant use with warfarin increases risk of bleeding
- Concomitant use with potassium-sparing diuretics increases risk of hyperkalemia
- Concomitant use with ACE inhibitors or ARBs increases risk of hypotension and renal dysfunction
Curated Content: Needs Vetting Before Put to Clinical Use